← Eichor
Study identifier: NCT06770296 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical Study

Condition: Breast Cancer  ·  Sponsor: The First Affiliated Hospital with Nanjing Medical University

PhasePhase 1
Planned participants200
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

Evaluate the safety and efficacy of Pyrotinib at different doses in combination with trastuzumab and paclitaxel chemotherapy for first-line treatment of HER2-positive advanced breast cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Yongmei Yin, Ph.D  ·  025-68307102  ·  ymyin@njmu.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Jiangsu Provincial People's HospitalNanjing, Jiangsu, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06770296